Top Page > Our Business

Our Business

The following companies are our main principals.

Click on the logo below to visit each website.

Agrochemex (U.K)


AgroChemex was established as an agricultural and horticultural contract research organization in 2000 and provides a truly independent class leading R&D facility.

Hypha Discovery (U.K.)


Hypha Discovery is working with companies worldwide to deliver solutions to pharma and agrochemical clients through the scalable production of human and other mammalian metabolites for MetID, use as analytical standards and for DMPK and toxicological assays. Hypha’s scalable microbial platform has a high success rate in producing both difficult-to-synthesise Phase I oxidative metabolites as well as glucuronides, sulfates and other conjugates, and can be employed to deliver milligram to gram amounts of pure metabolites.
Hypha has also developed a successful platform for lead diversification and late stage functionalisation of compounds through aliphatic and aromatic hydroxylations. The technology enables the identification of active metabolites, improvement of solubility and provides handles for further derivatisation.

Wavelength Pharmaceuticals (Israel) (formerly Perrigo API)

Wavelength Enterprises Ltd.

Wavelength Pharmaceuticals is an independent API company of choice for pharmaceutical industry leaders that require advanced API solutions to gain sustainable, competitive advantages. Founded in Israel in 1987 and active in Japan since 2002, with more than 250 customers in 50 countries, Wavelength’s cGMP-compliant facility is a first-class operation recognized for excellence in safety, and environmental stewardship having more than 30 years of exceptional regulatory track record with leading global regulatory authorities such as USFDA, EU-EMA, PMDA, TGA, KFDA, ANVISA and COFEPRIS. Wavelength has strong expertise in complex chemistry, innovative process development, crystalline forms and particle design and offers a wide range of APIs across many different therapeutic categories including Steroids, Hormones and Cytotoxics.

Pharmaron (U.K.)


Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism to chemical & pharmaceutical development. With over 4,000 employees and operations in China, the U.S. and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.

Quotient Sciences

Quotient Sciences

Quotient Sciences is dedicated to accelerating the development of new drugs for patients around the world.
We provide formulation development services, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry.
These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
We have manufacturing and clinical site in both UK and the US and provide integrated services globally.

Sandoz GmbH (Austria)

Sandoz COAI (Commercial Operations Anti-Infective & API) has production sites of APIs and Intermediates in Kundl/Austria, Barcelona, Lek/Slovenia as well as FDF (finished dosage forms) in Kundl/Austria and Lek/Slovenia. BioBridge is supporting sales of APIs, Intermediates and FDFs as well as relevant regulatory works.

Thomas Swan & Co. Ltd. (U.K.)


Founded in the United Kingdom in 1926, Thomas Swan & Co. Ltd. is a leading independent manufacturer of performance and speciality chemicals. The company manufactures over 100 products, from kilogramme to multi-tonne quantities, and offers an experienced and flexible custom manufacturing service. Thomas Swan has been active for more than 20 years in Japan. Thomas Swan exports to over 80 countries worldwide and is well placed to service the UK and international markets.